IBA Worldwide
IBA develops, manufactures and supports medical devices and software solutions for cancer treatment by proton beam therapy.
Launch date
Employees
Market cap
CAD588m
Enterprise valuation
CAD588m (Public information from Sep 2024)
Share price
€13.7 IBAB.BR
Ottignies-Louvain-la-Neuve Walloon Brabant (HQ)
Financials
Estimates*
EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 283m | 312m | 313m | 361m | 429m | 454m | 512m |
% growth | 36 % | 10 % | - | 15 % | 19 % | 6 % | 13 % |
EBITDA | 14.7m | 46.7m | 25.9m | 18.9m | 16.5m | - | - |
% EBITDA margin | 5 % | 15 % | 8 % | 5 % | 4 % | - | - |
Profit | 7.6m | 31.9m | 3.9m | 6.1m | (9.1m) | - | - |
% profit margin | 3 % | 10 % | 1 % | 2 % | (2 %) | - | - |
R&D budget | 31.1m | 33.1m | 34.0m | 41.8m | 47.9m | - | - |
R&D % of revenue | 11 % | 11 % | 11 % | 12 % | 11 % | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
Total Funding | - |
Related Content
Recent News about IBA Worldwide
EditInvestments by IBA Worldwide
EditACQUISITION by IBA Worldwide Feb 2024
ACQUISITION by IBA Worldwide May 2022